Building__O on__O the__O work__O of__O the__O Winstanley__B-ORG group__O prior__O to__O this__O impact__O period,__O when__O the__O research__O led__O to__O wider__O recognition__O that__O transmissible__O strains__O of__O P.__B-PER aeruginosa,__O and__O the__O LES__B-ORG in__O particular,__O are__O important__O in__O the__O context__O of__O CF,__O the__O group__O has__O achieved__O the__O following__O impacts:__O The__O multiplex__O PCR__O test__O for__O transmissible__O strains__O (combining__O Winstanley__O group__O designed__O PCR__B-MISC tests__O for__O the__O LES__B-ORG and__O Midlands1__B-MISC strains__O with__O a__O published__O PCR__O assay__O for__O the__O Manchester__B-ORG strain)__O has__O been__O used__O routinely__O in__O the__O NHS__B-ORG diagnostic__O laboratories__O serving__O both__O Adult__B-ORG (Liverpool__I-ORG Heart__I-ORG &amp;__I-ORG Chest__I-ORG Hospital)__I-ORG and__O Children's__B-LOC (Alder__I-LOC Hey__I-LOC Hospital)__I-LOC CF__I-LOC Units__I-LOC from__O 2008.__O
This__O therefore__O represents__O a__O new__O clinical__O product.__O
The__O clinical__O uptake__O of__O the__O multiplex__O PCR__B-ORG test__O has__O extended__O from__O local__O NHS__B-ORG to__O national__O level,__O as__O HPA__B-ORG Colindale__I-ORG used__O it__O as__O its__O main__O assay__O to__O test__O P.aeruginosa__B-LOC isolates__O from__O CF__B-ORG Units__I-ORG across__O the__O UK__B-LOC for__O the__O majority__O of__O the__O period__O Jan__O 2008__O to__O July__O 2013.__O
The__O PCR__B-MISC tests__O developed__O in__O Liverpool__B-ORG have__O helped__O in__O the__O recognition__O of__O the__O presence__O of__O the__O LES__O in__O other__O CF__O centres.__O
HPA__O Colindale__O receives__O thousands__O of__O P.__B-PER aeruginosa__O isolates__O each__O year__O from__O CF__B-ORG Units__I-ORG across__O the__O UK__B-LOC for__O strain__O typing.__O
Although__O they__O have__O more__O recently__O switched__O to__O wider__O use__O of__O an__O alternative__O typing__O method__O (VNTR),__B-ORG the__O PCR__B-ORG assays__O are__O still__O used__O occasionally__O by__O Public__B-ORG Health__I-ORG England,__I-ORG Colindale__I-ORG [10].__I-ORG
The__O LES__B-ORG remains__O the__O most__O common__O clone__O of__O P.__B-PER aeruginosa__O associated__O with__O CF__B-MISC infections__O in__O the__O UK__B-LOC (Martin__O et__O al.__O
2013__O J__B-ORG Med__I-ORG Microbiol__I-ORG on-__O line__O ahead__O of__O print).__O
The__O use__O of__O the__O multiplex__O PCR__O test__O has__O allowed__O clinicians__O to__O make__O informed__O decisions__O about__O patients__O with__O transmissible__O strains__O of__O P.__B-PER aeruginosa__O with__O respect__O to__O segregation__O of__O patients,__O because__O patients__O are__O cohorted__O for__O treatment__O depending__O on__O their__O microbiological__O status__O (ie.__O
LES-positive__O or__O LES-negative).__O
This__O has__O had__O an__O impact__O on__O the__O health__O of__O CF__B-ORG patients__O because__O the__O use__O of__O this__O test__O has__O contributed__O to__O the__O fact__O that__O new__O cases__O of__O LES__B-ORG infections__O are__O extremely__O rare__O in__O Liverpool.__B-LOC
The__O main__O beneficiaries__O are__O CF__O patients__O who__O are__O not__O yet__O infected__O with__O P.__B-PER aeruginosa.__O
Prior__O to__O the__O use__O of__O PCR__B-MISC tests__O to__O identify__O patients__O infected__O with__O transmissible__O strains,__O there__O was__O no__O patient__O segregation.__O
The__O consequence__O of__O this__O can__O be__O seen__O from__O the__O fact__O that__O prior__O to__O its__O discovery__O and__O the__O development__O of__O a__O simple__O test,__O the__O LES__B-ORG was__O already__O present__O in__O 80%__O of__O P.__O aeruginosa-infected__O patients__O in__O the__O Liverpool__B-ORG paediatric__O unit__O (Cheng__B-MISC et__I-MISC al__I-MISC 1996__I-MISC Lancet__B-ORG 348:639-642,__O Panagea__B-ORG et__I-ORG al.__O
2004__O Molecular__B-PER Diagnosis__I-PER 7:195-200).__O
Most__O of__O these__O patients__O have__O now__O moved__O on__O to__O the__O adult__O unit.__O
Because__O of__O effective__O segregation__O measures,__O there__O are__O now__O only__O small__O numbers__O of__O LES-infected__B-ORG patients__O at__O the__O Liverpool__B-ORG paediatric__O unit,__O and__O there__O have__O been__O no__O new__O cases__O for__O several__O years.__O
Cases__O in__O the__O paediatric__O CF__B-ORG Unit__I-ORG in__O Liverpool__B-ORG have__O decreased__O from__O 47__O LES-positive__B-ORG patients__O in__O 2003__O to__O 8__O LES-positive__O patients__O in__O 2009.__O
In__O the__O adult__O unit__O there__O was__O a__O reduction__O in__O the__O proportion__O of__O patients__O with__O LES__O (2003__O to__O 2009)__O from__O 71%__O to__O 53%__O [12,13].__O
Since__O 2009,__O there__O have__O been__O no__O new__O cases__O of__O LES-infected__B-MISC patients__O in__O the__O Adult__B-ORG CF__I-ORG Unit__I-ORG other__O than__O patients__O new__O to__O the__O unit__O (ie.__O
transferred__O from__O the__O paediatric__O centre__O or__O new__O to__O the__O region).__O
There__O is__O a__O clear__O clinical__O benefit__O to__O restricting__O the__O spread__O of__O the__O LES,__B-ORG which__O is__O associated__O with__O increased__O patient__O morbidity__O (Al-Aloul__O et__O al.__O
2004__O Thorax__O 59:334-336).__O
This__O increased__O morbidity__O has__O been__O shown__O to__O be__O true__O also__O for__O patients__O in__O North__B-LOC America__I-LOC infected__O with__O the__O LES__B-MISC (Aaron__I-MISC et__I-MISC al.__O
2010__O JAMA__O 304:2145-2153).__O
It__O is__O important__O to__O note__O that__O the__O impact__O of__O segregation__O based__O on__O genotyping__O is__O ongoing.__O
Patients,__O including__O new__O patients__O and__O first-time__O P.__B-PER aeruginosa__O infected__O patients,__O are__O regularly__O monitored__O using__O the__O PCR__B-ORG tests,__O enabling__O LES-positive__B-ORG patients__O to__O be__O treated__O apart__O from__O non-LES,__B-ORG and__O minimising__O the__O threat__O of__O further__O spread__O of__O the__O strain.__O
It__O is__O likely__O that__O there__O has__O also__O been__O impact__O at__O other__O CF__B-ORG centres.__O
Public__B-ORG Health__I-ORG England__I-ORG has__O confirmed__O that__O "Professor__B-PER Winstanley's__I-PER research__O has__O played__O an__O important__O role__O in__O the__O significant__O extensions__O of__O lifespan__O and__O quality__O of__O life__O improvements__O experienced__O by__O CF__O patients__O in__O England__B-LOC in__O the__O last__O few__O years"__O [10].__O
In__O addition,__O the__O research__O highlights__O the__O existence__O of__O transmissible__O strains__O of__O P.__B-PER aeruginosa__O (thought__O unlikely__O before__O Liverpool's__B-MISC initial__O LES__B-ORG report__O in__O 1996)__O has__O impacted__O on__O researchers__O worldwide__O and__O contributed__O to__O the__O discovery__O of__O other__O transmissible__O strains__O (Fothergill,__B-ORG Walshaw__I-ORG &amp;__I-ORG Winstanley__I-ORG 2012__O Eur__O Resp__O J__O 40:227-238),__O leading__O to__O changes__O in__O clinical__O procedures__O aimed__O at__O control__O of__O cross__O infection.__O
The__O use__O of__O our__O PCR__O assay__O is__O recommended__O in__O guidelines__O published__O by__O the__O UK__B-ORG Cystic__I-ORG Fibrosis__I-ORG Trust__I-ORG Microbiology__I-ORG Laboratory__I-ORG Standards__I-ORG Group__I-ORG designed__O to__O underpin__O the__O development__O of__O National__B-ORG Standard__I-ORG Operating__I-ORG procedures__O for__O the__O processing__O of__O respiratory__O samples__O submitted__O from__O people__O with__O Cystic__B-ORG Fibrosis__I-ORG [8].__I-ORG
This__O was__O circulated__O to__O all__O diagnostic__O laboratories__O in__O the__O UK__B-LOC serving__O CF__B-ORG units.__O
Hence,__O the__O assay__O has__O impacted__O on__O policy__O change.__O
